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Abstract 
Abstract 
Short communication on GUCY2C, with data on 
DNA/RNA, on the protein encoded and where the 
gene is implicated. 
Keywords 
GUCY2C, guanylin, uroguanylin, guanylyl cyclase 
C, cyclic GMP 
Identity 
Other names: DIAR6, GC-C, GUC2C, hSTAR, 
MECIL, MUCIL, STAR 
HGNC (Hugo): GUCY2C 
Location: 12p12.3 
 
 
Local order 
ATF7IP - PLBD1 - GUCY2C - H2AFJ - 
HIST4H4. 
DNA/RNA 
Description 
The GUCY2C gene is approximately 84 kb in 
length and has 27 exons. 
Transcription 
An approximately 3.8 mRNA is transcribed from 
the gene. 
Pseudogene 
None known. 
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SP: signal peptide; ECD: extracellular ligand binding domain; TM: transmembrane domain; KHD: regulatory kinase-homology 
domain; CAT: guanylyl cyclase catalytic domain; TAIL: C-terminal tail, interacts with scaffolding proteins. 
 
 
Protein 
Note 
GUCY2C encodes a guanylyl cyclase. 
Description 
1073 amino acid protein with guanylyl cyclase 
catalytic activity (4.6.1.2). 
Expression 
Primarily intestinal epithelial cells. Also expressed 
in hypothalamus and midbrain neurons. 
Localisation 
Apical membrane. 
Function 
In response to binding endogenous hormones 
guanylin and uroguanylin, or the exogenous ligand 
E. coli heat-stable enterotoxin, GUCY2C 
synthesizes cyclic GMP. Cyclic GMP activates 
downstream signaling pathways via cGMP-
dependent protein kinases, phosphodiesterases and 
cGMP-gated ion channels. 
Homology 
Adenylyl cyclase. 
Mutations 
Note 
- c.2519G→T  
This dominant missense mutation was identified in 
32 members of a Norwegian family, and was 
characterized as an activating mutation. Affected 
patients had mild chronic diarrhea and an increased 
risk for several GI disorders. The role of this 
mutation in cancer susceptibility remains unclear 
(Fiskerstrand et al., 2012).  
- c.1160A>G  
This recessive missense mutation was identified in 
a Bedouin family, and was characterized as an 
inactivating mutation. Affected patients had 
perinatal meconium ileus secondary to impaired 
GUCY2C-mediated fluid secretion. The role of this 
mutation in cancer susceptibility remains unclear 
(Romi et al., 2012).  
- c.2270dupA  
This recessive nonsense mutation was identified in 
a Bedouin family, and resulted in a premature stop 
codon two amino acids following the insertion 
which resulted in a truncated GUCY2C protein 
lacking its catalytic domain. Affected patients had 
perinatal meconium ileus secondary to impaired 
GUCY2C-mediated fluid secretion. The role of this 
mutation in cancer susceptibility remains unclear 
(Romi et al., 2012). 
Implicated in 
Colorectal cancer 
Note 
The endogenous GUCY2C ligands, guanylin and 
uroguanylin, are lost early in the neoplastic process, 
resulting in inactivation of downstream tumor 
suppressive GUCY2C signaling. Targeted deletion 
of GUCY2C in mice results in a phenotype of 
intestinal cancer susceptibility in the context of 
predisposing genetic mutations (apcmin) or exposure 
to carcinogen (azoxymethane). GUCY2C has a 
wide range of homeostatic functions in preventing 
tumorigenesis, including regulation of crypt 
proliferation, DNA damage repair and oncogenic 
signaling such as PI3K/Akt (Li et al., 2007a; Li et 
al., 2007b; Lin et al., 2010). 
Obesity 
Note 
GUCY2C is expressed in the hypothalamus, and 
targeted deletion in mice results in an obese 
phenotype which has been attributed to increased 
food consumption and dysregulated satiety. 
Importantly, the GUCY2C hormone ligand 
uroguanylin has been shown to mediate this effect. 
The uroguanylin peptide is released into the 
circulation postprandially and travels to the brain 
where it induces satiety in the hypothalamus, thus 
comprising a gut-brain neuroendocrine axis which 
regulates feeding (Valentino et al., 2011). 
Irritable bowel syndrome with 
constipation (IBS-C), and associated 
abdominal pain 
Note 
GUCY2C is a known mediator of intestinal fluid 
secretion. Work in mice and humans has 
demonstrated that the bacterial heat stable 
enterotoxin (ST) causes GI fluid secretion, motility 
and diarrhea via GUCY2C activation in the 
intestine. Recently, an oral GUCY2C ligand 
linaclotide (Linzess Ironwood Pharmaceuticals) 
was approved by the FDA for treatment of 
constipation-predominant irritable bowel syndrome 
(IBS). Further work has revealed a role for 
linaclotide in preventing GI pain associated with 
IBS. The mechanism for this effect is believed to be 
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release of cGMP by enterocytes from their 
basolateral membrane following ligand activation. 
This cGMP then inhibits nociception in adjacent 
visceral neurons, relieving pain (Chey et al., 2012; 
Castro et al., 2013). 
Inflammatory bowel disease (IBD) / 
colitis 
Note 
Work in mice has identified a possible role for 
GUCY2C in preventing colitis. Targeted deletion of 
GUCY2C results in more severe disease in a 
chemical model of colitis. Additionally, oral 
administration of GUCY2C ligand improved colitis 
in wild-type mice in the same model. These 
findings suggest a role for GUCY2C in regulating 
intestinal inflammation and associated disorders 
(Lin et al., 2012). 
Attention deficit hyperactivity 
disorder (ADHD) 
Note 
Work in mice has demonstrated the presence of 
GUCY2C in midbrain neurons, and targeted 
deletion of GUCY2C resulted in a phenotype of 
hyperactivity, which was reversible by treating with 
either ADHD therapeutics or an activator of 
downstream GUCY2C signaling (PKG activator) 
(Gong et al., 2011). 
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